Stability of polygenic scores across discovery genome-wide association studies
- PMID: 35199043
- PMCID: PMC8841810
- DOI: 10.1016/j.xhgg.2022.100091
Stability of polygenic scores across discovery genome-wide association studies
Abstract
Polygenic scores (PGS) are commonly evaluated in terms of their predictive accuracy at the population level by the proportion of phenotypic variance they explain. To be useful for precision medicine applications, they also need to be evaluated at the individual level when phenotypes are not necessarily already known. We investigated the stability of PGS in European American (EUR) and African American (AFR)-ancestry individuals from the Philadelphia Neurodevelopmental Cohort and the Adolescent Brain Cognitive Development study using different discovery genome-wide association study (GWAS) results for post-traumatic stress disorder (PTSD), type 2 diabetes (T2D), and height. We found that pairs of EUR-ancestry GWAS for the same trait had genetic correlations >0.92. However, PGS calculated from pairs of same-ancestry and different-ancestry GWAS had correlations that ranged from <0.01 to 0.74. PGS stability was greater for height than for PTSD or T2D. A series of height GWAS in the UK Biobank suggested that correlation between PGS is strongly dependent on the extent of sample overlap between the discovery GWAS. Focusing on the upper end of the PGS distribution, different discovery GWAS do not consistently identify the same individuals in the upper quantiles, with the best case being 60% of individuals above the 80th percentile of PGS overlapping from one height GWAS to another. The degree of overlap decreases sharply as higher quantiles, less heritable traits, and different-ancestry GWAS are considered. PGS computed from different discovery GWAS have only modest correlation at the individual level, underscoring the need to proceed cautiously with integrating PGS into precision medicine applications.
Keywords: Adolescent Brain Cognitive Development study; African American; PRS-CS; PTSD; Philadelphia Neurodevelopmental Cohort; UK Biobank; ancestry; height; methods development; type 2 diabetes.
© 2022 The Authors.
Conflict of interest statement
R.B. reports serving on the scientific board and owning stock in Taliaz Health, with no conflict of interest relevant to this work. The other authors declare no competing interests.
Figures
References
Grants and funding
- U24 DA041147/DA/NIDA NIH HHS/United States
- U01 DA051039/DA/NIDA NIH HHS/United States
- U01 DA041120/DA/NIDA NIH HHS/United States
- U01 DA051018/DA/NIDA NIH HHS/United States
- K23 MH120437/MH/NIMH NIH HHS/United States
- U24 DA041123/DA/NIDA NIH HHS/United States
- U01 DA051038/DA/NIDA NIH HHS/United States
- RC2 MH089924/MH/NIMH NIH HHS/United States
- U01 DA051037/DA/NIDA NIH HHS/United States
- U01 DA051016/DA/NIDA NIH HHS/United States
- U01 DA041117/DA/NIDA NIH HHS/United States
- RC2 MH089983/MH/NIMH NIH HHS/United States
- U01 DA041174/DA/NIDA NIH HHS/United States
- P50 HD105351/HD/NICHD NIH HHS/United States
- U01 DA041093/DA/NIDA NIH HHS/United States
- U01 DA041134/DA/NIDA NIH HHS/United States
- U01 DA041022/DA/NIDA NIH HHS/United States
- U01 DA041156/DA/NIDA NIH HHS/United States
- U01 DA050987/DA/NIDA NIH HHS/United States
- U01 DA041025/DA/NIDA NIH HHS/United States
- U01 DA050989/DA/NIDA NIH HHS/United States
- U01 MH119690/MH/NIMH NIH HHS/United States
- U01 DA041089/DA/NIDA NIH HHS/United States
- U01 DA050988/DA/NIDA NIH HHS/United States
- U01 MH119739/MH/NIMH NIH HHS/United States
- U01 DA041106/DA/NIDA NIH HHS/United States
- U01 DA041028/DA/NIDA NIH HHS/United States
- U01 DA041048/DA/NIDA NIH HHS/United States
- U01 DA041148/DA/NIDA NIH HHS/United States
- R01 MH119219/MH/NIMH NIH HHS/United States
LinkOut - more resources
Full Text Sources
